[Acquired tumor "robustness" in the case of prostate cancer].
Tumors are highly robust and maintain their proliferative potential against both a wide range of host-defense mechanisms and anticancer therapies. In this study, we investigated the levels of human leukocyte antigen (HLA) class I, multi-drug resistance 1 (MDR1), and androgen receptor (AR) expressions in untreated prostate cancers harvested by radical prostectomy. The mean percentages of cancer cells expressing HLA class I, MDR1, and AR among the 10 cancer samples were 41, 35, and 74%, respectively. In addition, double-staining of HLA class I and MDR1 revealed the four definite populations (HLA class I(+)/MDR(+), HLA class I(+)/MDR(-), HLA class I (-)/MDR(+), and HLA class I(-)/MDR(-)) in cancer tissues from the majority of cancer patients tested, and the mean percentages of cells expressing these combinations were 13, 29, 22, and 38%, respectively. Similar results were obtained by double staining of HLA class I and AR, except for 2 cases in which HLA class I(-)/AR (+) cancer cells predominated. These results indicated that untreated prostate cancer cells acquired a wide range of genomic mutation, which may have been caused by internal host pressure to eliminate malignant cells, and would provide evidence of the robustness of untreated prostate cancer.
Homma
Shigenori
S
Dept. of Immunology, Kurume University School of Medicine.
Noguchi
Masanori
M
Sato
Yuji
Y
Maeda
Yoshiaki
Y
Shomura
Hiroki
H
Komohara
Yoshihiro
Y
Mine
Takashi
T
Harada
Mamoru
M
Yamada
Akira
A
Todo
Satoru
S
Itoh
Kyogo
K
D000368:Aged; D018432:Drug Resistance, Multiple / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D011944:Receptors, Androgen / Q000032:analysis
D006680:HLA Antigens; D011944:Receptors, Androgen